Telmisartan in patients with hypertension and chronic kidney disease – modify the dose or not? Review article
Article Sidebar
Published:
Mar 31, 2017
Keywords:
chronic kidney disease, nephropathy, hypertension, ARB, telmisartan
Main Article Content
Abstract
Chronic kidney disease (CKD) is well recognized cardiovascular risk factor. One of the factors leading to end-stage renal disease is poorly controlled hypertension. Nephroprotective efficacy of telmisartan, comparable with ramipril, was established in ONTARGET trial. The use of telmisartan in patients with CKD does not require dose adjustment.
Article Details
How to Cite
Chmielewski , M., Kuch , M., & Pawlaczyk, K. (2017). Telmisartan in patients with hypertension and chronic kidney disease – modify the dose or not?. Medycyna Faktow (J EBM), 10(1(34), 26-29. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2189
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Zasady postępowania w nadciśnieniu tętniczym – 2015 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadciśnienie Tętnicze w Praktyce 2015; 1(1): 1-70.
2. Król E.: Przewlekła choroba nerek: klasyfikacja, epidemiologia, diagnostyka. Forum Nefrologiczne 2008; 1(1): 1-6.
3. Yusuf S., Teo K.K., Pogue J. et al.; ONTARGET Investigators: Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. 2008; 358: 1547-1559.
4. Yusuf S., Teo K., Anderson C. et al.; TRANSCEND Investigators: Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Telmisartan Randomised Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (TRANSCEND). Lancet 2008; 372(9644): 1174-1183.
5. NKF K/DOQI Clinical Practice Guidelines for chronic kidney disease: evaluation, classification, and stratification. J. Kidney Dis. Am. 2002; 39(2, supl. 1): S1-S266.
6. Levey A.S., Eckhardt K.-U., Tsukamoto Y. et al.: Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005; 67: 2089-2100.
7. Prejbisz A., Januszewicz A.: Działania niepożądane i środki ostrożności przy stosowaniu antagonistów receptora angiotensyny II. Choroby Serca i Naczyń 2006; 3(4): 195-202.
8. Konieczny G., Posadzy-Małaczyńska A., Tykarski A.: Działania niepożądane inhibitorów konwertazy angiotensyny. Choroby Serca i Naczyń 2006; 3(3): 140-148. 9. Telmisartan – Charakterystyka Produktu Leczniczego.
2. Król E.: Przewlekła choroba nerek: klasyfikacja, epidemiologia, diagnostyka. Forum Nefrologiczne 2008; 1(1): 1-6.
3. Yusuf S., Teo K.K., Pogue J. et al.; ONTARGET Investigators: Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. 2008; 358: 1547-1559.
4. Yusuf S., Teo K., Anderson C. et al.; TRANSCEND Investigators: Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Telmisartan Randomised Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (TRANSCEND). Lancet 2008; 372(9644): 1174-1183.
5. NKF K/DOQI Clinical Practice Guidelines for chronic kidney disease: evaluation, classification, and stratification. J. Kidney Dis. Am. 2002; 39(2, supl. 1): S1-S266.
6. Levey A.S., Eckhardt K.-U., Tsukamoto Y. et al.: Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005; 67: 2089-2100.
7. Prejbisz A., Januszewicz A.: Działania niepożądane i środki ostrożności przy stosowaniu antagonistów receptora angiotensyny II. Choroby Serca i Naczyń 2006; 3(4): 195-202.
8. Konieczny G., Posadzy-Małaczyńska A., Tykarski A.: Działania niepożądane inhibitorów konwertazy angiotensyny. Choroby Serca i Naczyń 2006; 3(3): 140-148. 9. Telmisartan – Charakterystyka Produktu Leczniczego.